1-13 of 13
Cathy Zhou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

Paolo Ghia, William G. Wierda, Paul M. Barr, Thomas J. Kipps, Tanya Siddiqi, John N. Allan, Zoë Hunter, Cathy Zhou, Anita Szoke, James P. Dean, Constantine S. Tam
Journal: Blood
Blood (2023) 142 (Supplement 1): 633.
https://doi.org/10.1182/blood-2023-187128
Published: 2023
Journal Articles

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Xavier C. Badoux, Jacqueline C. Barrientos, Alessandra Tedeschi, Stephen Opat, Ian W. Flinn, Eva Gonzalez Barca, Ryan Jacobs, Edith Szafer-Glusman, Cathy Zhou, Anita Szoke, William G. Wierda, Paolo Ghia, Constantine S. Tam
Journal: Blood
Blood (2022) 140 (Supplement 1): 224–227.
https://doi.org/10.1182/blood-2022-160338
Published: 2022
Journal Articles

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Clinical Trials & Observations
Constantine S. Tam, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Ryan Jacobs, Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jackson, Bryone J. Kuss, Carol Moreno, Edith Szafer-Glusman, Kristin Russell, Cathy Zhou, Joi Ninomoto, James P. Dean, William G. Wierda, Paolo Ghia
Journal: Blood
Blood (2022) 139 (22): 3278–3289.
https://doi.org/10.1182/blood.2021014488
Published: 2022
Includes: Supplemental data
Journal Articles

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Paolo Ghia, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Stephen Opat, Ian W. Flinn, Xavier C. Badoux, Alessandra Tedeschi, Eva Gonzalez-Barca, John M. Pagel, Ryan Jacobs, Jacqueline Barrientos, Edith Szafer-Glusman, Cathy Zhou, Joi Ninomoto, James P. Dean, Constantine S. Tam, William G. Wierda
Journal: Blood
Blood (2021) 138 (Supplement 1): 68.
https://doi.org/10.1182/blood-2021-144544
Published: 2021
Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

William G. Wierda, MD PhD, Constantine S. Tam, MD, John N. Allan, MD, Tanya Siddiqi, MD, Thomas J. Kipps, MD PhD, Stephen Opat, FRACP, FRCPA, MBBS, Alessandra Tedeschi, MD, Xavier C. Badoux, MBBS, FRACP, FRCPA, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Sharon Jackson, MD, Carol Moreno, MD PhD, Ryan Jacobs, MD, John M. Pagel, MD PhD, Ian W. Flinn, MD PhD, Cathy Zhou, MS, Edith Szafer-Glusman, PhD, Joi Ninomoto, PharmD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Paolo Ghia, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-134446
Published: 2020
Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Constantine S. Tam, MBBS, MD, Tanya Siddiqi, MD, John N. Allan, MD, Thomas J. Kipps, MD PhD, Ian W. Flinn, MD PhD, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Stephen Opat, Paul M. Barr, MD, Alessandra Tedeschi, MD, Ryan Jacobs, MD, Xavier C. Badoux, MBBS, FRACP, FRCPA, Paolo Ghia, MD PhD, Juthamas Sukbuntherng, PhD, Ahmed Hamed Salem, PhD FCP, Kristin Russell, BS, Karl Eckert, BA, Cathy Zhou, MS, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 35.
https://doi.org/10.1182/blood-2019-121424
Published: 2019
Journal Articles

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Carol Moreno, MD PhD, Richard Greil, MD, Fatih Demirkan, MD, Alessandra Tedeschi, MD, Bertrand Anz, MD, Loree Larratt, MD, Martin Simkovic, MD PhD, Olga Samoilova, MD, Jan Novak, MD PhD, Dina Ben-Yehuda, MD, Vladimir Strugov, MD, Devinder Gill, MD MRCP, FRCPath, John G. Gribben, Emily Hsu, PhD, Cathy Zhou, MS, Fong Clow, ScD, Danelle F. James, MD MAS, Lori Styles, MD, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 691.
https://doi.org/10.1182/blood-2018-99-111370
Published: 2018
Journal Articles

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Paul Barr, MD, Tadeusz Robak, MD PhD, Carolyn J Owen, Alessandra Tedeschi, Osnat Bairey, MD, Nancy L Bartlett, MD, Jan Burger, MD PhD, Peter Hillmen, Steven Coutre, MD, Stephen Devereux, PhD FRCP, FRCPath, Sebastian Grosicki, MD PhD, Helen McCarthy, MBBS, PhD, Jianyong Li, MD, David Simpson, Fritz Offner, MD, Carol Moreno, MD, Cathy Zhou, MS, Lori Styles, MD, Danelle F. James, MD MAS, Thomas J. Kipps, MD, PhD, Paolo Ghia, MD PhD
Journal: Blood
Blood (2016) 128 (22): 234.
https://doi.org/10.1182/blood.V128.22.234.234
Published: 2016
Journal Articles

Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

Jennifer A. Woyach, MD, Peter Hillmen, Jennifer R. Brown, MD PhD, Steven E. Coutre, MD, Paul Barr, MD, Susan M. O'Brien, MD, Jacqueline C. Barrientos, MD, Stephen Devereux, PhD FRCP, FRCPath, Neil E. Kay, MD, Nishitha Reddy, MD MSCI, MBBS, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Alessandra Tedeschi, Cathy Zhou, MS, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, John C. Byrd, MD, Jan Burger, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2041.
https://doi.org/10.1182/blood.V128.22.2041.2041
Published: 2016
Journal Articles

Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2 TM )

Alessandra Tedeschi, MD, Paul M. Barr, MD, Tadeusz Robak, MD PhD, Carolyn Owen, MD, Paolo Ghia, MD PhD, Osnat Bairey, MD, Peter Hillmen, MB, ChB, PhD, Nancy L Bartlett, MD, Jianyong Li, MD, David Simpson, MBBS, Sebastian Grosicki, MD PhD, Stephen Devereux, FRCP, FRCPath, PhD, Helen McCarthy, FRCP, FRCPath, PhD, Steven Coutre, MD, Hang Quach, MD, Gianluca Gaidano, MD PhD, Zvenyslava Maslyak, MD, Don A. Stevens, MD, Ann Janssens, MD, Fritz Offner, MD PhD, Jiří Mayer, MD, Michael O'Dwyer, MD, Andrzej Hellmann, MD PhD, Anna Schuh, MD PhD, Tanya Siddiqi, MD, Aaron Polliack, MD, Constantine S. Tam, MBBS, Michael Keating, MBBS, Deepali Suri, MS, Cathy Zhou, MS, Fong Clow, ScD, Lori Styles, MD, Danelle F. James, MD MAS, Thomas J. Kipps, MD, PhD, Jan A. Burger, MD PhD
Journal: Blood
Blood (2015) 126 (23): 495.
https://doi.org/10.1182/blood.V126.23.495.495
Published: 2015
Journal Articles

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

Clinical Trials & Observations
John C. Byrd, Richard R. Furman, Steven E. Coutre, Jan A. Burger, Kristie A. Blum, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Yun Shaw, Elizabeth Bilotti, Cathy Zhou, Danelle F. James, Susan O'Brien
Journal: Blood
Blood (2015) 125 (16): 2497–2506.
https://doi.org/10.1182/blood-2014-10-606038
Published: 2015
Includes: Supplemental data
Journal Articles

Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant

Steven Coutre, MD, Susan O'Brien, MD, John C. Byrd, MD, Peter Hillmen, MB, ChB, PhD, Jennifer R. Brown, Martin JS Dyer, Anthony R. Mato, MD, David B. Miklos, Michael Keating, MBBS, Cathy Zhou, MS, Maria Fardis, PhD MBA, Lori Styles, MD, Samantha Jaglowski, MD MPH
Journal: Blood
Blood (2014) 124 (21): 4697.
https://doi.org/10.1182/blood.V124.21.4697.4697
Published: 2014
Journal Articles

The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma

Nathan H Fowler, MD, Ranjana H Advani, MD, Jeff Sharman, MD, Sonali M. Smith, MD, Jesse McGreivy, MD, Lori Kunkel, MD, Vina Troung, Cathy Zhou, Thomas E. Boyd, MD
Journal: Blood
Blood (2012) 120 (21): 156.
https://doi.org/10.1182/blood.V120.21.156.156
Published: 2012